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Abstract 
In autoantibody-mediated autoimmune diseases, autoantibody profiling allows to stratify 
patients and link autoantibodies with disease severity and outcome. However, in immune-
mediated thrombotic thrombocytopenic purpura patients, stratification according to antibody 
profiles and their clinical relevance has not been fully explored. We aimed at developing a new 
type of autoantibody profiling assay for immune-mediated thrombotic thrombocytopenic 
purpura based on the use of anti-idiotypic antibodies. Anti-idiotypic antibodies against 3 anti-
spacer autoantibodies were generated in mice and were used to capture the respective anti-
spacer idiotopes from 151 acute immune-mediated thrombotic thrombocytopenic purpura 
plasma samples. We next deciphered these anti-spacer idiotope profiles in immune-mediated 
thrombotic thrombocytopenic purpura patients and investigated if these limited idiotope 
profiles could be linked with disease severity. We developed 3 anti-idiotypic antibodies that 
recognized particular idiotopes in the anti-spacer autoantibodies II-1, TTP73 or I-9, that are 
involved in ADAMTS13 binding. Thirty-five, 24 and 42% of patients were positive for antibodies 
with the II-1, TTP73 and I-9 idiotopes, respectively. Stratifying patients according to the 
corresponding 8 anti-spacer idiotope profiles revealed an until now unknown insight into the 
anti-spacer II-1, TTP73 and I-9 idiotope profiles in these patients. Finally, these limited idiotope 
profiles showed no association with disease severity. We successfully developed 3 anti-idiotypic 
antibodies that allowed us to determine the profiles of the anti-spacer II-1, TTP73 and I-9 
idiotopes in immune-mediated thrombotic thrombocytopenic purpura patients. Increasing the 
number of patients and/or future development of additional anti-idiotypic antibodies against 
other anti-ADAMTS13 autoantibodies might allow to identify idiotope profiles of clinical, 
prognostic value. 
 
Keywords
 autoimmune disease, antibody profiling, anti-idiotypic antibody, thrombotic 
thrombocytopenic purpura, ADAMTS13 
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Introduction 
In autoantibody-mediated autoimmune diseases, patients develop autoantibodies against self-
antigens.
1
 The autoantibody response can be directed to multiple self-antigens like in systemic 
sclerosis
2
, Sjögren syndrome
3
 and type 1 diabetes
4
 or to a single self-antigen like myasthenia 
gravis
5
 and Graves’ disease.
6
 Patients suffering from the autoimmune disorder immune-
mediated thrombotic thrombocytopenic purpura (iTTP) present with an autoantibody response 
against one antigen, the von Willebrand factor (VWF) cleaving protease ADAMTS13 (A 
Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, member 13).
7,8
 
Deficiency in ADAMTS13 leads to accumulation of hyper-active ultra-large VWF multimers that 
spontaneously interact with platelets. The resulting microthrombi block arterioles and 
capillaries, which leads to severe thrombocytopenia, hemolytic anemia and organ failure. The 
VWF cleaving protease ADAMTS13 consists of 14 domains: the metalloprotease (M), disintegrin-
like (D), cysteine-rich (C) and spacer (S) domains, 8 thrombospondin type 1 repeats (T1-8) and 2 
CUB domains.
9
 It is known that the anti-ADAMTS13 autoimmune response in iTTP patients is 
polyclonal but 80-100% of patients possess autoantibodies targeting the cysteine-rich and 
spacer domain.
7,10–12
 The standard treatment for iTTP is plasma exchange (PEX) often in 
combination with immunosuppressive agents (mainly steroids and rituximab).
8
 Recently, the 
anti-VWF nanobody caplacizumab, used as a frontline therapy together with PEX hastened TTP 
recovery, opening promising perspectives to improve the prognosis of the disease.
13,14
 
Splenectomy is only performed in the most severe patients, when other measures have 
failed.
8,15
 
Since autoimmune diseases manifest differently among patients and have a chronic course with 
recurring acute bouts, biomarkers are identified that allow patient stratification to predict 
disease outcome and prognosis and to adapt specific treatment.
16
 Obviously, autoantibodies are 
useful biomarkers in autoimmune diseases and autoantibody profiling has been shown to be 
valuable in stratifying patients with autoimmune disorders.
17,18
 On the one hand, autoantibody 
profiling approaches are based on the binding of the patient autoantibodies to the disease 
causing antigen (recombinant proteins, fragments thereof or peptides).
19,20
 Whereas, on the 
other hand, autoantibody profiling can be done independent of the antigen using anti-idiotypic 
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antibodies that recognize autoantibodies that bind to the antigen (Figure 1).
21
 Anti-idiotypic 
antibodies can be generated by immunizing mice with purified or cloned antigen-binding 
antibodies.
22–24
 Antibodies that bind to particular idiotopes involved in antigen binding can next 
be used to detect specific autoantibodies in patient plasma or serum.
21
 Finally, even if the 
disease-causing antigen is not known, antibody profiling can lead to the identification of 
disease-linked peptides using next generation sequencing
25
 and mass spectrometry
26,27
 of the 
total antibody response in autoimmune disease patients. 
Also iTTP is a chronic disease with a variable disease outcome and risk for relapse.
28
 Levels of 
ADAMTS13 activity, anti-ADAMTS13 autoantibody subtypes, ADAMTS13 antigen levels or a 
combination thereof have been used to identify patient groups with a worse disease outcome 
or a higher risk for relapse.
28–35
 Although the outcome of the different studies is variable, it has 
been shown for example that an ADAMTS13 activity < 10% during acute disease is linked with 
an increased risk for relapse
35
 and that presenting anti-ADAMTS13 autoantibody and 
ADAMTS13 antigen levels predict prognosis.
31
 In addition, prognostic scoring systems based on 
clinical and or laboratory parameters have been set up to predict severe cases and patients at 
risk; from 1987 with the Rose index
36,37
, to more recently the PLASMIC score
38
 and the score by 
Benhamou et al..
39
 The predictive model set up by Benhamou and colleagues takes into account 
age, lactate dehydrogenase (LDH) levels and cerebral involvement and detects early death in 
acquired severe ADAMTS13 deficiency-associated idiopathic TTP.
39
 However, in iTTP, 
autoantibody profiling has not been extensively explored yet to stratify patients. 
 
In this project, we developed an autoantibody profiling assay for iTTP using anti-idiotypic 
antibodies that recognize particular idiotopes on anti-ADAMTS13 autoantibodies, idiotopes that 
are involved in ADAMTS13 binding (Figure 1). Since the ADAMTS13 spacer domain seems to be 
the main immunogenic region targeted in these patients
29
, we generated an anti-idiotypic 
antibody against 3 available cloned human anti-spacer autoantibodies. The selected anti-
idiotypic antibodies were then used to screen 151 iTTP plasmas for the presence of 
autoantibodies with the same idiotopes across patients, which resulted in stratification of iTTP 
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patients according to these anti-spacer idiotope profiles. We next investigated in a subgroup of 
95 patients whether certain anti-spacer idiotope profiles could be linked with disease severity.  
 6
Methods 
Immunization strategy and characterization of anti-II-1, anti-TTP73 and anti-I-9 antibodies 
Anti-II-1, anti-TTP73 and anti-I-9 antibodies were developed by immunizing BALB/c mice (Janvier 
Labs, Le Genest-Saint-Isle, France) with the cloned human anti-spacer autoantibodies II-1
40
, 
TTP73, or I-9
41
, respectively (see immunization strategy in Supplemental methods). The binding 
of purified anti-II-1, anti-TTP73 or anti-I-9 antibodies to II-1, TTP73 and I-9 respectively and to 
the conserved regions (Figure 1, grey) in human immunoglobulin G (IgG) antibodies were 
identified using ELISA (see ‘ELISA to study the binding of murine anti-II-1, anti-TTP73 and anti-I-9 
antibodies to coated human anti-spacer autoantibodies II-1, TTP73 and I-9 and, to a pool of 
human IgG antibodies’ in Supplemental material and methods).  
 
ELISA to identify anti-II-1, anti-TTP73 and anti-I-9 antibodies that inhibit the binding of 
respectively anti-spacer autoantibodies II-1, TTP73 or I-9 to ADAMTS13 
Human anti-spacer autoantibodies II-1, TTP73 or I-9 (constant final EC50: 0.04, 0.85 and 0.04 
µg/mL, respectively; see Supplemental methods), were pre-incubated with a 1 in 2 dilution 
series of murine anti-II-1, anti-TTP73 or anti-I-9 antibodies (final start concentration 10 µg/mL) 
respectively, in a pre-blocked plate. After 30 minutes, samples were transferred to a 
recombinant human (rh)ADAMTS13 (2.7 µg/mL in phosphate buffered saline (PBS)) coated 
plate. Bound human anti-spacer autoantibodies II-1, TTP73 or I-9 were detected using a mixture 
of HRP-labelled anti-human IgG
1-4
 (IgG
1
: 1/20,000 and IgG
2-4
: 1/2,000; Sanquin, Amsterdam, The 
Netherlands) (see Supplemental methods for more details).  
 
ELISA to study the binding of the anti-idiotypic antibodies to the anti-spacer idiotopes of II-1, 
TTP73 and I-9 
Murine anti-idiotypic antibodies 17H9 (anti-II-1 antibody), 9G12 (anti-TTP73 antibody) and 7D10 
(anti-I-9 antibody) were coated at 5 µg/mL in carbonate/bicarbonate coating buffer (50mM 
Na
2
CO
3
/NaHCO
3
, pH 9.6). After blocking, human anti-spacer autoantibodies II-1, TTP73 and I-9 
were added at a start concentration of 1 µg/mL and further 1 in 2 diluted. Bound anti-spacer 
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autoantibodies were detected by adding a mixture of anti-human IgG
1-4
-HRP antibodies 
(Sanquin) (see Supplemental methods for more details).  
 
Patient samples 
Detailed information about the 151 iTTP plasma samples can be found in Supplemental 
methods ‘Patient samples’. The study protocol was approved by the Medical Ethical Committee 
of the University Medical Center Utrecht (Utrecht, The Netherlands), the Ethics Committee of 
Hospital Pitié-Salpêtrière and Hospital Saint-Antoine (Paris, France) and the Ethics Committee of 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milan, Italy), and was in 
accordance with the Declaration of Helsinki. 
 
ELISA to identify the presence of anti-spacer idiotope profiles in plasmas of acute iTTP 
patients using the newly developed anti-idiotypic antibodies 
Murine anti-idiotypic antibody 17H9 (anti-II-1 antibody), 9G12 (anti-TTP73 antibody) or 7D10 
(anti-I-9 antibody) were coated at 5 µg/mL. After blocking, patient plasma (start dilution 10%, 
v/v) was added and 1 in 2 diluted. Bound patient antibodies were detected with anti-human 
IgG
1-4
-HRP (Sanquin) (see Supplemental methods for more details).  
 
Statistical analysis 
Graphpad Prism v5.03 software (GraphPad Software Inc., San Diego, CA, USA) was used for 
statistical analysis (see Supplemental methods for more details).  
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Results 
Development of anti-idiotypic antibodies against idiotopes in anti-spacer autoantibodies II-1, 
TTP73 or I-9 involved in ADAMTS13 binding  
To generate anti-idiotypic antibodies recognizing particular idiotopes in anti-spacer 
autoantibodies involved in ADAMTS13 binding, three cloned human anti-spacer autoantibodies 
with different epitopes and inhibitory characteristics were available: II-1
40
, TTP73
42
 and I-9
41
 
(see supplemental material and methods) and were used to immunize BALB/c mice. As the 
injected anti-spacer autoantibodies are full IgG antibodies in which the variable regions are 
grafted on a human IgG1 constant region
40,41
, the mice developed antibodies that either 
recognized conserved regions (e.g. constant regions: C
H
 and C
L
 and framework regions in V
H
 and 
V
L
; Figure 1, grey parts) or idiotopes in the complementarity determining regions (CDRs) of the 
V
H
 and V
L
 of II-1, TTP73 and I-9 (Figure 1, dark and light blue dots). We obtained 1 mouse 
monoclonal antibody that recognized anti-spacer autoantibody II-1, 2 that recognized anti-
spacer autoantibody TTP73 and 10 that recognized anti-spacer autoantibody I-9 (Figure 2A) as 
the generated antibodies bound to the coated anti-spacer autoantibodies II-1, TTP73 or I-9, 
respectively. To identify which of the generated monoclonal antibodies recognized the 
conserved part of the human autoantibodies (C
H
, C
L
 and framework regions in V
H
 and V
L
; Figure 
1, grey parts), their binding to a pool of purified human IgG antibodies was studied. Monoclonal 
antibody 17H9 recognizing anti-spacer autoantibody II-1 did not recognize the conserved part of 
the coated human IgG antibodies (Figure 2B), while 1 of the monoclonal antibodies (20H3) 
recognizing anti-spacer autoantibody TTP73 and 9 of the monoclonal antibodies (1E6, 5C8, 6C9, 
7E8, 9F9, 9G9, 9H4, 11F7, and 14G6) recognizing anti-spacer autoantibody I-9 did bind to the 
conserved part of the coated human IgG antibodies (Figure 2B). Hence, monoclonal antibodies 
17H9, 9G12 and 7D10 are anti-idiotypic antibodies that target idiotopes in the CDRs of V
H
 and V
L
 
of respectively anti-spacer autoantibody II-1, TTP73 or I-9 (Figure 2B). 
We next aimed to identify if the anti-idiotypic antibodies recognizing particular idiotopes in the 
anti-spacer autoantibodies II-1, TTP73 and I-9 are anti-idiotypic antibodies that are involved in 
ADAMTS13 binding (Figure 1, dark blue antibody). To do so, we used a competition ELISA where 
we studied if the binding of anti-spacer autoantibodies II-1, TTP73 and I-9 could be inhibited by 
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their respective anti-idiotypic antibody. The 3 developed anti-idiotypic antibodies (17H9, 9G12 
and 7D10) inhibited the binding of their respective anti-spacer autoantibodies (II-1, TTP73 and I-
9) to rhADAMTS13 (Figure 2C). Figure 2D summarizes the developed murine anti-II-1, anti-TTP73 
and anti-I-9 antibodies targeting the conserved region of the antibody (grey) or the anti-
idiotypic antibodies specific for the idiotopes present in the CDRs (in red, green, orange) of anti-
spacer autoantibody II-1, TTP73 and I-9 respectively. 
In conclusion, we developed 3 anti-idiotypic antibodies that recognize particular idiotopes in the 
anti-spacer autoantibodies II-1, TTP73 and I-9 that are involved in ADAMTS13 binding, as they 
strongly inhibit the binding of anti-spacer autoantibodies II-1, TTP73 or I-9, respectively, to 
rhADAMTS13. 
 
Anti-idiotypic antibodies and their binding to idiotopes in II-1, TTP73 and I-9 
Since anti-spacer autoantibodies II-1 and I-9 have overlapping but different epitopes (see 
Supplemental methods)
43
, they will have both shared and unique idiotopes. We therefore 
investigated whether anti-idiotypic antibodies developed against anti-spacer autoantibody II-1 
(17H9) and I-9 (7D10) recognized shared or unique idiotopes in II-1 and I-9. As a control, we 
included the anti-idiotypic antibody 9G12 developed against the anti-spacer autoantibody 
TTP73, which does not have an overlapping epitope with II-1 and I-9. 
The anti-idiotypic antibody against anti-spacer autoantibody II-1 (17H9) recognized a unique 
idiotope in II-1 as it only captured II-1 and not anti-spacer autoantibodies I-9 and TTP73 (Figure 
3A). As expected, the anti-idiotypic antibody against TTP73 (9G12) also recognized a unique 
idiotope in anti-spacer TTP73 as it only captured TTP73 and not anti-spacer autoantibodies II-1 
and I-9 (Figure 3B). In contrast, the anti-idiotypic antibody (7D10) against the anti-spacer I-9 
idiotope captured both anti-spacer autoantibody I-9 and II-1 (Figure 3C) showing that anti-
idiotypic antibody 7D10 recognizes a common idiotope in II-1 and I-9.  
In conclusion, these data show that the anti-idiotypic antibodies against anti-spacer 
autoantibody II-1 (17H9) and TTP73 (9G12) recognize a unique idiotope in II-1 and TTP73 
respectively, whereas the anti-idiotypic antibody developed against anti-spacer autoantibody I-9 
(7D10) recognizes an idiotope present in both anti-spacer autoantibodies II-1 and I-9 (Figure 3). 
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Identification of anti-spacer idiotope profiles in plasmas of acute iTTP patients using the 
newly developed anti-idiotypic antibodies 
In a first step, we screened the plasmas of 151 iTTP patients for the presence or absence of the 
anti-spacer II-1, TTP-73 and I-9 idiotopes using the 3 newly developed anti-idiotypic antibodies. 
In a second step, we stratified the patients according to their anti-spacer idiotope profile. 
The 151 iTTP plasma samples were all collected during an acute iTTP episode (see detailed 
information in Supplemental methods). All patients presented with severe ADAMTS13 
deficiency (< 10% activity) and detectable anti-ADAMTS13 IgG titers. Anti-ADAMTS13 IgG titers 
ranged from 16 to ≥100 IU/mL (median: 87 IU/mL, Figure 4). Of the 151 iTTP patients, 34% 
(52/151) were positive for antibodies with the anti-spacer II-1 idiotope (recognized by anti-
idiotypic antibody 17H9) (Figure 4A, red dots) with median anti-spacer II-1 idiotope levels of 47 
ng/mL (Figure 4A, red squares). Twenty-five percent (37/151) of the patients were positive for 
antibodies with anti-spacer TTP73 idiotope (recognized by anti-idiotypic antibody
 
9G12) (Figure 
4B, green dots) with median anti-spacer TTP73 idiotope levels of 174 ng/mL (Figure 4B, green 
squares). Forty-two percent (63/151) of the patients were positive for antibodies with anti-
spacer I-9 idiotope (recognized by anti-idiotypic antibody
 
7D10) (Figure 4C, orange dots) with 
median anti-spacer I-9 idiotope levels of 57 ng/mL (Figure 4C, orange squares). 
We next stratified the acute iTTP patients according to their anti-spacer idiotope profile (Figure 
5). The 8 possible profiles correspond to the presence of either 1, 2, 3 or none of the 3 anti-
spacer idiotopes. All 8 anti-spacer idiotope profiles were identified in the iTTP patient cohort 
(n=151) (Figure 5). In 28% (42/151) of the patients, only one particular idiotope could be 
detected in the plasma, with 8% (12/151) having the II-1 idiotope (profile 1), 4% (6/151) having 
the TTP73 idiotope (profile 2) and 16% (24/151) having the I-9 idiotope (profile 3). In 19% 
(28/151) of the patients, 2 idiotopes were identified in their antibody repertoire, with 5% 
(7/151) having II-1 and TTP73 idiotopes (profile 4), 10% (15/151) having II-1 and I-9 idiotopes 
(profile 5) and 4% (6/151) having I-9 and TTP73 idiotopes (profile 6). In 12% (18/151) of the 
patients all 3 idiotopes were present in their antibody repertoire (profile 7). In 42% (63/151) of 
the patients none of the 3 idiotopes were detected (profile 8).  
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In conclusion, using the 3 developed anti-idiotypic antibodies, we here for the first time 
unraveled the specific II-1, TTP73 and I-9 idiotope profiles in iTTP patients and showed that 58% 
of the patients had antibodies with II-1, TTP73 and I-9 idiotopes in their plasma and this in 
different combinations while 42% of the patients were negative for these idiotopes.  
 
Anti-spacer idiotope profiles and their possible link with disease severity 
We next investigated whether the identified anti-spacer idiotope profiles (Figure 5) could be 
linked with disease severity, although the number of patients per profile group was rather low 
and we only screened for the presence or absence of 3 anti-spacer idiotopes. As a measure of 
disease severity, we studied disease outcome and applied treatment strategy. This part of the 
study was performed on the 95 patients of the French Reference Center for TMA, as detailed 
information on laboratory, clinical and outcome parameters were available for these patients 
(Supplemental Table 2).  
We first analyzed whether the anti-spacer idiotope profiles could be linked with disease 
outcome. Disease outcome was previously identified in the patients at time of diagnosis by 
determining a score defined by Benhamou et al..
39
 This score (either 1, 2, 3 or 4) is a risk score 
for early death in TTP based on 3 factors related to clinical and biological presentation (age, high 
LDH levels and cerebral involvement). A score of ≥ 3 has a positive predictive value for mortality 
(patients at risk for 30-day mortality after treatment initiation) and a score < 3 has a negative 
predictive value.
39
 To check whether the disease outcome parameter could be linked with 
specific anti-spacer idiotope profiles, we performed chi-square-based analysis. However, none 
of the anti-spacer idiotope profiles could be linked with a score of ≥ 3 (chi square, non-
significant) (Figure 6A). In line with this, there was no link between the anti-spacer idiotope 
profiles and the individual factors related to the score by Benhamou et al..
39
 (age: ANOVA, non-
significant; cerebral involvement and high LDH levels: chi square, non-significant) (Supplemental 
Figure 1).  
We next used the same approach to investigate whether anti-spacer idiotope profiles could be 
linked with the applied treatment strategy. We therefore compared the anti-spacer idiotope 
profiles in patients treated with PEX with/without rituximab and patients treated with PEX 
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with/without rituximab and additional treatment(s) (either steroids or other 
immunosuppressive drugs, e.g. cyclophosphamide, bortezomib; or/and caplacizumab or/and 
splenectomy; Supplemental Table 2). However, also treatment could not be linked with anti-
spacer idiotope profiles (chi square, non-significant) (Figure 6B). 
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Discussion 
In this paper, we successfully generated 3 anti-idiotypic antibodies that specifically recognized 
the idiotopes of anti-spacer autoantibodies II-1, TTP73 and I-9. With this anti-idiotypic assay, we 
could for the first time identify the presence or absence of anti-spacer II-1, TTP73 and I-9 
idiotopes in iTTP patients. In addition, grouping the patients according to the absence or 
presence of one, two or three of the anti-spacer idiotopes, revealed an until now unknown 
insight into the anti-spacer II-1, TTP73 and I-9 idiotopes in these patients. Although the resulting 
idiotope profiles could not be linked with disease severity, our data show that anti-idiotypic 
antibodies are interesting tools to determine an antibody profile in patients with any 
autoimmune disease.  
 
Many studies have used groups of ADAMTS13 domains to identify which ADAMTS13 domains 
(e.g. MDTCS, MDT, CS, T2-C2, T2-T8, C1-C2) are targeted by anti-ADAMTS13 autoantibodies in 
individual iTTP patients. All these studies concluded that the immune response in iTTP patients 
is polyclonal with an immuno-dominant epitope in the cysteine-spacer domain.
8,10–12,29,43–45
 
Antibody profiling based on these data, stratifies patients according to either the presence or 
absence of anti-ADAMTS13 antibodies against (a) certain domain(s). Only 2 studies investigated 
the link between domain specificity of anti-ADAMTS13 antibodies and disease severity or 
platelet counts. Thomas et al.
29
 stratified iTTP patients according to having either anti-MDTCS or 
anti-T2-C2 autoantibodies but could not identify a link with disease severity while Zheng et al.
10
 
reported an inverse correlation between the presence of IgG antibodies against the T2-T8 
and/or C1-C2 domains and platelet counts on admission. In our study, we used anti-idiotypic 
antibodies to stratify iTTP patients according to the presence or absence of anti-ADAMTS13 
antibodies with specific idiotopes. By using an anti-idiotypic antibody, we can hence investigate 
whether a specific anti-ADAMTS13 idiotope is present or absent in an iTTP patient. Indeed, with 
our 3 anti-idiotypic antibodies, we determined the until now unknown anti-spacer II-1, TTP73 
and I-9 idiotope profiles in 151 iTTP patients in acute phase. Eighteen of the 151 iTTP patients 
had all 3 anti-spacer idiotopes in their plasma, 63 patients had none of the anti-spacer idiotopes 
and 70 patients had either one or a combination of 2 of the anti-spacer idiotopes in their 
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plasma, showing that the presence of these 3 anti-spacer idiotopes is not a common feature in 
iTTP patients. In addition, anti-spacer autoantibody II-1
40
 used in this study, is a well 
characterized iTTP patient autoantibody that targets the R568-F592-R660-Y661-Y665 epitope in 
the ADAMTS13 spacer domain
43
 and is a strong inhibitor of ADAMTS13 activity
40
. Although 
about 50% of the iTTP patients have inhibitory anti-ADAMTS13 autoantibodies
29,46
, it is currently 
not known if all these patients have a II-1 idiotope in their plasma. Using our anti-idiotypic 
antibody against the anti-spacer II-1 idiotope, we now provided insight into the incidence of this 
anti-spacer II-1 idiotope in iTTP patients. Indeed, our study showed that only 34% of the 
patients had this anti-spacer idiotope in their plasma. Insight into the diversity of inhibitory anti-
ADAMTS13 autoantibodies that target the R568-F592-R660-Y661-Y665 epitope is important in 
view of the development of a targeted antibody therapy. In addition, anti-idiotypic antibodies 
allow to study epitope spreading observed in iTTP patients by following the presence of specific 
idiotopes in function of time. An additional advantage of using anti-idiotypic antibodies for 
antibody profiling is that the antigen itself is not needed for the profiling assay.
21,47
 Production 
of recombinant ADAMTS13 and its fragments in the case of iTTP is more expensive and complex 
than producing and purifying murine anti-idiotypic antibodies.  
Finally, we investigated whether we could establish a link between these anti-spacer idiotope 
profiles and disease severity (disease outcome and applied treatment strategy). However, the 
current idiotope profiles did not allow to identify specific profiles that are linked with disease 
severity. On the one hand, this can be due to the relative low number of patients per idiotope 
profile. Hence, increasing the number of patients in each idiotope profile could result in a link 
between certain profiles and disease severity. On the other hand, although that majority of iTTP 
patients do have autoantibodies against the cysteine-spacer domain, autoantibodies targeting 
other regions within or outside the cysteine-spacer domain could be of relevance, as the 
immune response is polyclonal. Hence, multiple anti-idiotypic antibodies recognizing a large 
number of anti-ADAMTS13 autoantibodies might be needed to identify autoantibody profiles in 
iTTP that predict disease outcome or that are linked with treatment. We are therefore currently 
expanding our panel of anti-idiotypic antibodies with anti-idiotypic antibodies recognizing anti-
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ADAMTS13 autoantibodies outside the spacer domain to identify autoantibody profiles of 
clinical, prognostic value. 
 
The strength of autoantibody profiling to predict disease severity and outcome in an 
autoimmune disorder where autoantibodies are developed against a single self-antigen has 
been clearly demonstrated for example in myasthenia gravis. Indeed, it has been shown that the 
presence of autoantibodies against a specific epitope in AChR is linked with disease severity in 
these patients.
48,49
 Hence, future development of anti-idiotypic antibodies against anti-
ADAMTS13 autoantibodies that are linked with disease severity, outcome and relapse remains a 
promising approach to personalize treatment of iTTP patients. 
 
In conclusion, we have shown that anti-idiotypic antibodies are useful to unravel anti-spacer 
autoantibody specificity in iTTP patients. Moreover, this approach is broadly applicable and can 
therefore be translated to perform autoantibody profiling in any antibody-mediated 
autoimmune disease. 
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Figure Legends 
Figure 1: Anti-idiotypic antibodies directed against different idiotopes in autoantibodies A 
representative autoantibody is illustrated with the variable regions of heavy (V
H
) and light (V
L
) 
chains and the constant regions of heavy (C
H
) and light (C
L
) chains. Variable regions consist of 
framework regions and complementarity determining regions (CDRs). The CDRs are unique 
among antibodies and consist of idiotopes that are involved in binding to the (self-) antigen 
(dark blue dots) and idiotopes that are not involved in binding to the (self-) antigen (light blue 
dots). All other regions are conserved regions (grey) between different antibodies and comprise 
the framework regions of the V
H
 and V
L
 and the constant regions of C
H
 en C
L
 
chains. Anti-
idiotypic antibodies (Abs) bind to idiotopes involved in (self-) antigen binding and hence inhibit 
the binding of the autoantibody to the (self-) antigen are depicted in dark blue. Anti-idiotypic 
antibodies that bind to idiotopes not involved in binding to the (self-) antigen are depicted in 
light blue. Anti-conserved region antibodies are depicted in grey. 
 
Figure 2: Development and characterization of anti-idiotypic antibodies that inhibit the 
binding of respectively anti-spacer autoantibody II-1, TTP73 or I-9 to rhADAMTS13 (A) Binding 
of purified murine anti-II-1 (red), anti-TTP73 (green) and anti-I-9 (orange) antibodies to coated 
human anti-spacer autoantibodies II-1, TTP73 or I-9. Bound murine anti-II-1, anti-TTP73 and 
anti-I-9 antibodies were detected using GAM-HRP. Murine anti-II-1, anti-TTP73 or anti-I-9 
antibody binding was expressed as relative absorbance values (mean ± SD, n=3) with 
absorbance of the respective positive controls (sera of mice immunized with either II-1, TTP73 
or I-9) set as 1. (B) Binding of purified murine anti-II-1 (red), anti-TTP73 (green) and anti-I-9 
(orange) antibodies to a coated human IgG pool. Bound murine anti-II-1, anti-TTP73 and anti-I-9 
antibodies were detected using GAM-HRP. Murine anti-II-1, anti-TTP73 or anti-I-9 antibody 
binding was expressed as relative absorbance values (mean ± SD, n=3) with absorbance of the 
respective positive controls (sera of mice immunized with either II-1, TTP73 or I-9) set as 1. 
Binding to coated human IgG pool indicates that the murine antibodies bind to the conserved 
regions of antibodies. (C) Inhibition of anti-spacer autoantibody binding to rhADAMTS13 by anti-
idiotypic antibodies. A 1 in 2 dilution of murine anti-II-1 (red), anti-TTP73 (green) or anti-I-9 
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antibodies (orange) were pre-incubated with constant amounts of respectively anti-spacer 
autoantibody II-1, TTP73 and I-9 before addition to a rhADAMTS13 coated 96-well microtiter 
plate. Bound II-1 (red), TTP73 (green) and I-9 (orange) antibodies were detected using a mixture 
of anti-human IgG
1-4
-HRP. Data are expressed as % binding (mean ± SD, n=3) of anti-spacer 
autoantibodies II-1 (red), TTP73 (green) or I-9 (orange) to rhADAMTS13 in the presence of the 
competing murine anti-II-1 (17H9), anti-TTP73 (9G12) or anti-I-9 (7D10) antibody relative to the 
binding of II-1, TTP73 or I-9 in the absence of anti-idiotypic antibodies (dotted lines). (D) 
Overview of the binding sites of the generated anti-II-1, anti-TTP73 and anti-I-9 antibodies in II-1 
(red), TTP73 (green) and I-9 (orange) respectively. 
 
Figure 3: Anti-idiotypic antibodies and their binding to the anti-spacer idiotopes of II-1, TTP73 
and I-9 Binding of human anti-spacer autoantibodies (autoAbs) II-1 (red), TTP73 (green), I-9 
(orange) and of a pool of human IgG antibodies (negative control, black) to coated murine anti-
idiotypic antibody (Ab) 17H9 developed against II-1 (A), 9G12 developed against TTP73 (B) and 
7D10 developed against I-9 (C). Bound human anti-spacer autoantibodies II-1, TTP73 and I-9 
were detected using a mixture of anti-human IgG
1-4
-HRP. Data are expressed as relative 
absorbance values (mean ± SD, n=3) with absorbance of binding of II-1, TTP73 and I-9 at 1 
µg/mL to their respective anti-idiotypic antibodies set as 1. 
 
Figure 4: Total anti-ADAMTS13 IgG titers and anti-spacer II-1, TTP73 and I-9 idiotope 
concentrations in acute iTTP patients (A-C) Total anti-ADAMTS13 IgG titers (IU/mL) were 
determined via TECHNOZYM® with exception of 3 samples (ID 124, 128 and 130) which were 
determined via an in house developed anti-ADAMTS13 IgG ELISA (Supplemental Table 1, 
indicated by §). Anti-spacer II-1 (red square) (A), TTP73 (green square) (B) and I-9 (orange 
square) (C) idiotope concentrations were determined by adding patient plasma to coated 
murine anti-idiotypic antibody 17H9 (A), 9G12 (B) or 7D10 (C). Bound human autoantibodies 
were detected using a mixture of anti-human IgG
1-4
-HRP. A dilution series of human anti-spacer 
autoantibodies II-1 (A), TTP73 (B) or I-9 (C) was used as a calibration curve to determine 
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idiotope concentrations (ng/mL). Median is represented for total anti-ADAMTS13 IgG titers and 
II-1, TTP73 and I-9 idiotope concentrations. 
 
Figure 5: Anti-spacer idiotope profiles in acute iTTP patients Acute iTTP patients (n=151) were 
stratified according to the presence (+) or absence (-) of II-1, TTP73 and I-9 idiotopes as 
determined in Figure 4.  
 
Figure 6: Disease outcome and treatment according to the anti-spacer idiotope profiles 
Stratification of the 95 acute iTTP patients of the French Reference Center for TMA according to 
the 8 idiotope profiles for (A) the scoring system of Benhamou et al.
39
 (score < 3, white bars; 
score ≥ 3, black bars) and for (B) treatment with plasma exchange (PEX) with/without rituximab 
(white bars) or PEX with/without rituximab and additional treatments(s) (black bars). Three 
patients were excluded as they deceased before treatment initiation (Supplemental Table 2, 
indicated by †). 
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Supplemental methods 
Animals 
Animal experiments were approved by the Institutional animal Care and Use Committee of KU Leuven, 
Belgium (project number P055/2015). Mice were anesthetized using isoflurane/O2 before subcutaneous 
or intra-peritoneal injections and retro-orbital venipuncture. Serum was obtained from blood samples by 
1 hour incubation at 37°C and centrifugation at 13,400 rpm for 10 minutes. Serum samples were stored at 
-20°C. 
 
Cloned human anti-spacer autoantibodies 
Three cloned human anti-spacer autoantibodies with different epitopes and different inhibitory 
characteristics were used for the development of anti-idiotypic antibodies: anti-spacer autoantibody II-11, 
TTP732 and I-93. Anti-spacer autoantibody II-1 targets the R568-F592-R660-Y661-Y665 epitope in 
ADAMTS13’s spacer domain4 and is a strong inhibitor of ADAMTS13 activity1. Anti-spacer autoantibody I-
9 targets the R568-R660-Y661-Y665 epitope4 and is a weak inhibitor of ADAMTS13 activity1. Anti-spacer 
autoantibody TTP732 recognizes an epitope in ADAMTS13 that does not overlap with the epitope of anti-
spacer autoantibodies II-1 and I-9 (epitope at the amino acid level not known) and does not inhibit 
ADAMTS13 activity.  
2 
 
 
Immunization strategy and characterization of anti-II-1, anti-TTP73 and anti-I-9 antibodies 
Immunization strategy 
BALB/c mice (Janvier Labs, Le Genest-Saint-Isle, France) were immunized with cloned human anti-spacer 
autoantibodies II-11, TTP732, or I-93. Briefly, for each antibody, mice were injected subcutaneously with 10 
µg antibody (either II-1, TTP73, or I-9) in complete Freund’s adjuvant (BD, Franklin Lakes, NJ, USA) at day 
1 and intraperitoneally with 10 µg of antibody in incomplete Freund’s adjuvant (BD) at day 14. Mice 
immunized with vehicle only were used as a negative control. Twenty-one days after the first 
immunization, blood samples were taken to detect the presence of murine anti-human II-1, TTP73 and I-
9 antibodies in ELISA (see below). The immune response in mice was boosted at day 56 and 58 by injection 
of each antibody (either II-1, TTP73, or I-9). At day 59, the presence of murine anti-human II-1, TTP73 and 
I-9 antibodies in mouse sera was confirmed using ELISA (see below). At day 60, mice were sacrificed and 
their spleens were isolated. Spleen cells were fused with SP2/0 myeloma cells to generate hybridoma cells 
according to the method of Köhler and Milstein.5 Fourteen days after fusion, media of the cultured 
hybridoma cells was screened for the presence of either anti-II-1, anti-TTP73 or anti-I-9 antibodies using 
ELISA (see below). Hybridoma cells positive for anti-II-1, anti-TTP73 or anti-I-9 antibodies were further 
cultured and anti-II-1, anti-TTP73 or anti-I-9 antibodies were purified from the culture medium using 
protein G sepharose affinity chromatography (ÄKTA, GE Healthcare, Waukesha, WI, USA). Antibody 
concentration was determined by measuring absorbance at 280 nm and antibody purity was checked via 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein blue staining 
(Westburg, Leusden, The Netherlands). The binding of the purified anti-II-1, anti-TTP73 or anti-I-9 
antibodies to II-1, I-9 and TTP73 respectively was confirmed in ELISA (see below). ELISAs to identify the 
anti-idiotypic antibodies amongst the anti-II-1, anti-TTP73 or anti-I-9 antibodies are described below. The 
finally selected anti-idiotypic antibodies 17H9 (anti-II-1 antibody), 9G12 (anti-TTP73 antibody) and 7D10 
(anti-I-9 antibody) were subcloned as described elsewhere6 and purified as described above. 
 
ELISA to study the binding of murine anti-II-1, anti-TTP73 and anti-I-9 antibodies to coated human anti-
spacer autoantibodies II-1, TTP73 and I-9  
A 96-well microtiter plate was coated with either anti-spacer autoantibody II-1 (1.5 µg/mL), TTP73 (5 
µg/mL) or I-9 (1.5 µg/mL in carbonate/bicarbonate coating buffer; 50mM Na2CO3/NaHCO3, pH 9.6) and 
incubated overnight at 4°C. Next, the plate was washed and blocked with 3% milk powder in phosphate 
buffered saline (PBS) (blocking buffer). Either sera (start dilution 10%, v/v) from mice injected with anti-
3 
 
spacer autoantibody II-1, TTP73 or I-9 or media (start dilution, 17%, v/v) from the anti-II-1, anti-TTP73 and 
anti-I-9 producing hybridoma cells or purified murine anti-II-1, anti-TTP73 and anti-I-9 antibodies (start 
concentration 1 µg/mL) were added to the respectively II-1, TTP73 or I-9 coated 96-well microtiter plates 
and a 1 in 2 dilution series was made. For each plate, a serum sample (21 days post first immunization, 
1/500 start dilution) of mice immunized with either II-1, TTP73 or I-9 respectively was used as a positive 
control. Sera samples taken before immunization, naïve culture media or anti-glycoprotein Ib antibody 
6B47 were used as a negative control respectively. Bound anti-II-1, anti-TTP73, or anti-I-9 antibodies were 
detected using horse radish peroxidase (HRP)-labelled goat anti-mouse (GAM) antibodies (1/10,000; 
Jackson ImmunoResearch, West Grove, PA, USA). Colouring reaction was performed using ortho-
phenylenediamine dihydrochloride (OPD) and H2O2 and stopped with 4M sulfuric acid. Absorbance was 
measured at 490 nm. Data for the II-1, TTP73 or I-9 ELISA’s were expressed as relative absorbance values 
(mean ± SD, n=3) with absorbance of the respective positive controls (sera of mice immunized with either 
II-1, TTP73 or I-9) set as 1. 
 
ELISA to study the binding of murine anti-II-1, anti-TTP73 and anti-I-9 antibodies to a pool of human IgG 
antibodies 
Murine anti-II-1, anti-TTP73 and anti-I-9 antibodies targeting the conserved regions (Figure 1, grey) in 
human immunoglobulin G (IgG) antibodies were identified using ELISA. A pool of human IgG antibodies (5 
µg/mL in carbonate/bicarbonate coating buffer; Sigma-Aldrich, Saint-Louis, MO, USA) was coated on a 96-
well  microtiter plate. Plates were blocked with blocking buffer and murine anti-II-1, anti-TTP73 and anti-
I-9 antibodies were added (5 µg/mL) and a 1 in 2 dilution series was made. For each plate, a serum sample 
(21 days post first immunization, 1/500 start dilution) of mice immunized with either II-1, TTP73 or I-9 
respectively was used as a positive control. The anti-glycoprotein Ib antibody 6B47 was used as a negative 
control. Bound murine anti-II-1, anti-TTP73 and anti-I-9 antibodies were detected with GAM-HRP 
(1/10,000; Jackson ImmunoResearch). Colouring reaction was performed as described above and 
absorbance was measured at 490 nm. Data for the II-1, TTP73 or I-9 ELISA’s were expressed as relative 
absorbance values (mean ± SD, n=3) with absorbance of the respective positive controls (sera of mice 
immunized with either II-1, TTP73 or I-9) set as 1. 
 
ELISA to identify anti-II-1, anti-TTP73 and anti-I-9 antibodies that inhibit the binding of respectively anti-
spacer autoantibodies II-1, TTP73 or I-9 to ADAMTS13 
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ELISA to determine the effective concentration at half maximal binding (EC50) of each anti-spacer 
autoantibody to ADAMTS13 
The EC50 of the anti-spacer autoantibodies II-1, TTP73 and I-9 was determined via ELISA. A 96-well 
microtiter plate was coated with recombinant human (rh)ADAMTS13 (15nM in PBS) and incubated 
overnight at 4°C. After blocking, the anti-spacer autoantibodies II-1, TTP73 or I-9 were added (10 µg/mL) 
and a 1 in 2 dilution series was made. Bound anti-spacer autoantibodies II-1, TTP73 or I-9 were detected 
using HRP-labelled rabbit anti-human IgG and IgM antibodies (1/10,000; Jackson ImmunoResearch). 
Colouring reaction was performed as described above and absorbance was measured at 490 nm. Binding 
curves were fitted using specific binding with Hill slope to determine EC50 for each anti-spacer 
autoantibody (Graphpad Prism v5.03 software Inc., San Diego, CA, USA). The determined EC50 for anti-
spacer autoantibody II-1, TTP73 and I-9 are respectively 0.04, 0.85 and 0.04 µg/mL. 
ELISA to identify inhibiting anti-II-1, anti-TTP73 and anti-I-9 antibodies 
Human anti-spacer autoantibodies II-1, TTP73 or I-9 (constant final EC50) were pre-incubated with a 1 in 
2 dilution of murine anti-II-1, anti-TTP73 or anti-I-9 antibodies (final start concentration 10 µg/mL) 
respectively, in a pre-blocked plate. After 30 minutes, samples were transferred to a rhADAMTS13 (15nM 
in PBS) coated 96-well microtiter plate. Bound human anti-spacer autoantibodies II-1, TTP73 or I-9 were 
detected using a mixture of HRP-labelled anti-human IgG1-4 (IgG1: 1/20,000 and IgG2-4: 1/2,000; Sanquin, 
Amsterdam, The Netherlands). Colouring reaction was performed as described above and absorbance was 
measured at 490 nm. Binding (%) of anti-spacer autoantibodies II-1, TTP73 or I-9 to rhADAMTS13 in the 
presence of the competing murine anti-II-1 (17H9), anti-TTP73 (9G12) or anti-I-9 (7D10) antibody was 
expressed relative to binding of respectively II-1, TTP73 or I-9 with no competing antibody (buffer only) to 
rhADAMTS13 (set at 100% binding). Data were expressed as mean ± SD (n=3). 
 
ELISA to study the binding of the anti-idiotypic antibodies to the anti-spacer idiotopes of II-1, TTP73 and 
I-9 
Murine anti-idiotypic antibodies 17H9 (anti-II-1 antibody), 9G12 (anti-TTP73 antibody) and 7D10 (anti-I-9 
antibody) (5 µg/mL in carbonate/bicarbonate coating buffer) were coated on 96-well microtiter plates. 
After blocking, human anti-spacer autoantibodies II-1, TTP73 and I-9 were added at a start concentration 
of 1 µg/mL and 1 in 2 serial diluted. Addition of a pool of human Immunoglobulin G (IgG) antibodies (Sigma-
Aldrich Saint-Louis, MO, USA) was included as a negative control. Bound anti-spacer autoantibodies were 
detected by adding a mixture of HRP-labelled anti-human IgG1-4 antibodies (IgG1: 1/20,000 and IgG2-4: 
1/2,000; Sanquin). Colouring reaction was performed as described above and absorbance was measured 
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at 490 nm. Data were expressed as relative absorbance values (mean ± SD, n=3) with absorbance of binding 
of II-1, TTP73 and I-9 at 1 µg/mL to anti-idiotypic antibodies 17H9 (anti-II-1 antibody), 9G12 (anti-TTP73 
antibody) and 7D10 (anti-I-9 antibody) respectively set as 1.  
 
Patient samples 
Plasma samples were collected from 151 iTTP patients during acute phase before treatment. All patients 
presented with TTP-related clinical signs (thrombocytopenia, microangiopathic haemolytic anaemia), 
ADAMTS13 activity <10% measured via FRETS-VWF73 assay (Peptides International, Louisville, KY, USA)8 
with exception of 2 samples that were measured using the collagen binding assay (CBA, patient’s ID 128 
and 131, Supplemental Table 1 indicated by *)9 and anti-ADAMTS13 IgG titer >15 IU/mL measured via the 
TECHNOZYM ADAMTS13-INH ELISA® kit (Technoclone, Vienna, Austria) with exception of 3 samples that 
were measured using an in house anti-ADAMTS13 IgG ELISA (patient’s ID 124, 128 and 129, Supplemental 
Table 1 indicated by §). Patients were diagnosed with idiopathic iTTP (without any underlying cause). 
Twenty-one plasma samples were derived from the University Medical Center Utrecht (The Netherlands), 
35 samples from the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of Milan (Italy) and 95 
plasma samples from the French Reference Center for Thrombotic MicroAngiopathies (TMA) (France).  
Besides age, sex, total anti-ADAMTS13 IgG titer and ADAMTS13 activity, detailed information on 
laboratory, clinical and outcome parameters was available for the 95 iTTP patients enrolled in the French 
Reference Center for TMA (Supplemental Table 2). Laboratory parameters such as platelet count and 
lactate dehydrogenase (LDH) levels (except for 10 patients) were available (Supplemental Table 2). 
Assessment of cerebral involvement at time of diagnosis included clinical signs including headaches, 
confusion, aphasia, transient focal defects, convulsion, seizure, stroke and/or coma. Treatment consisted 
of either plasma exchange (PEX) with/without rituximab, or PEX with/without rituximab supplemented 
with additional treatment(s); steroids, other immunosuppressive drugs (e.g. cyclophosphamide, 
bortezomib) and/or caplacizumab and/or splenectomy. Patient’s outcome was investigated in terms of 
the pre-defined scoring system established by Benhamou et al. which includes age (years), LDH level 
(elevated LDH level: ≥ 2500 IU/L) and cerebral involvement.10 
 
ELISA to identify the presence of anti-spacer idiotope profiles in plasmas of acute iTTP patients using the 
newly developed anti-idiotypic antibodies 
Ninety-six-well microtiter plates were coated with either murine anti-idiotypic antibody 17H9 (anti-II-1 
antibody), 9G12 (anti-TTP73 antibody) or 7D10 (anti-I-9 antibody) (5 µg/mL in carbonate/bicarbonate 
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coating buffer) and incubated overnight at 4°C. After blocking, patient plasma (start dilution 10%, v/v) was 
added and 1 in 2 serial diluted. Bound patient antibodies (antibodies with the same idiotopes as the anti-
spacer autoantibodies II-1, TTP73, or I-9), were detected with HRP-labelled anti-human IgG1-4 (IgG1: 
1/20,000 and IgG2-4: 1/2,000; Sanquin). Colouring reaction was performed as described above and 
absorbance was measured at 490 nm. The human anti-spacer autoantibodies II-1, TTP73 or I-9 were used 
to set up a calibration curve. Anti-spacer autoantibody II-1 (0.25 µg/mL), TTP73 (1.25 µg/mL) or I-9 (0.25 
µg/mL) were spiked in a normal human plasma pool of 10 healthy donors (NHP; start dilution 10%, v/v) 
and 1 in 2 serial diluted. The equation derived after linear regression was used to determine respectively 
II-1, TTP73 or I-9 idiotope levels (ng/mL) in patient samples. As a negative control, NHP was added in each 
assay in triplicate and used to define the Lower Limit of Detection (LLoD, mean of negative control + 3*SD) 
for the II-1, TTP73 and I-9 idiotope screening ELISA (LLoDII-1 idiotope = 0.8 ng/mL, LLoDTT773 idiotope= 3.9 ng/mL 
and LLoDI-9 idiotope = 0.8 ng/mL). 
 
Statistical analysis 
Graphpad Prism v5.03 software (GraphPad Software Inc.) was used for statistical analysis. Continuous 
variables were described as mean and standard deviation (SD) and categorical variables as counts and 
percentages. Continuous (age) and categorical (categorized LDH levels, cerebral involvement, score system 
by Benhamou et al.10 and treatment) data were compared using ANOVA and chi square tests, respectively. 
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Supplemental Figure + Figure Legends 
 
Supplemental Figure 1: Separate parameters included in the score by Benhamou et al.10 according to the 
anti-spacer idiotope profiles Stratification of the 95 acute iTTP patients of the French Reference Center 
for TMA according to the 8 idiotope profiles for (A) age, (B) lactate dehydrogenase (LDH) levels (normal 
levels, white bars; elevated levels: ≥ 2500 IU/L, black bars) and (C) cerebral involvement (no cerebral 
involvement, black bars; cerebral involvement, white bars). Ten patients were excluded since no LDH 
measurement was performed (Supplemental Table 2, indicated by N/A). 
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Supplemental Tables + Table Legends 
Supplemental Table 1: ADAMTS13 activity, anti-ADAMTS13 IgG, anti-spacer II-1, anti-spacer TTP73 and 
anti-spacer I-9 idiotopes of iTTP patients during acute TTP Identity (ID), ADAMTS13 activity (%) using 
FRETS-VWF73 assay or collagen binding assay (*), anti-ADAMTS13 IgG titer (IU/mL) via TECHNOZYM® or 
in-house anti-ADAMTS13 IgG ELISA (§), anti-spacer II-1 idiotope, anti-spacer TTP73 idiotope and anti-
spacer I-9 idiotope levels (ng/mL) of 151 acute iTTP patients. ‘x’ indicates no detectable anti-spacer 
idiotopes. 
 
ID 
ADAMTS13 
activity (%) 
anti-ADAMTS13 
IgG (IU/mL) 
anti-spacer II-1 
idiotope (ng/mL) 
anti-spacer TTP73 
idiotope (ng/mL) 
anti-spacer I-9 
idiotope (ng/mL) 
1 < 5 56 75 x 70 
2 < 5 78 29 x x 
3 < 5 22 x x 121 
4 < 10 18 49 556 70 
5 < 5 100 49 x 91 
6 < 5 100 x x x 
7 < 5 100 x x x 
8 < 5 64 x x x 
9 < 5 100 x x x 
10 < 5 100 144 412 146 
11 < 5 100 x x x 
12 < 5 31 19 x 120 
13 < 5 100 x x 44 
14 < 5 57 x x x 
15 < 5 85 x x x 
16 < 5 100 141 x x 
17 < 5 100 x x x 
18 < 5 98 x x x 
19 < 5 29 x x x 
20 < 5 100 x x x 
21 < 5 100 x x x 
22 < 5 100 38 x 26 
23 < 5 57 x x 24 
24 < 5 29 x 116 x 
25 < 5 100 75 165 71 
26 < 5 90 x x x 
27 < 5 26 26 147 88 
28 < 5 59 37 392 38 
29 < 5 56 53 122 62 
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30 < 5 100 x x 125 
31 < 5 100 52 133 x 
32 < 5 100 124 439 83 
33 < 5 100 19 916 x 
34 < 5 100 23 x x 
35 < 5 100 x 394 x 
36 < 5 68 x x x 
37 < 5 58 191 333 x 
38 < 5 69 35 124 x 
39 < 5 69 x x 355 
40 < 5 32 5 x 22 
41 < 5 100 x x x 
42 < 5 45 31 x 34 
43 < 5 77 x 162 28 
44 < 5 100 x x 31 
45 < 5 52 x 156 16 
46 < 5 100 x x x 
47 < 5 100 x x 14 
48 < 5 100 69 87 96 
49 < 5 27 x x x 
50 < 5 67 29 x x 
51 < 5 38 22 x x 
52 < 5 80 x x x 
53 < 5 87 x x x 
54 < 5 100 x x x 
55 < 5 100 x x 7 
56 < 5 87 x x x 
57 < 5 100 74 109 635 
58 < 5 100 102 x 77 
59 < 5 100 18 x 59 
60 < 5 100 x x 63 
61 < 5 100 164 359 345 
62 < 5 44 28 196 118 
63 < 5 76 43 x 157 
64 < 5 100 119 174 132 
65 < 5 60 27 x 45 
66 < 10 24 x x x 
67 < 5 58 x x x 
68 < 5 18 x x 259 
69 < 5 100 x 746 38 
70 < 5 89 x x 83 
71 < 5 65 16 x 90 
72 < 5 36 23 x 45 
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73 < 5 44 x x 59 
74 < 5 100 x 114 35 
75 < 10 100 x x 40 
76 < 5 100 16 54 47 
77 < 5 24 x x 45 
78 < 10 18 29 51 75 
79 < 5 100 57 x 52 
80 < 5 100 x x x 
81 < 5 80 x x 113 
82 < 5 100 x 65 47 
83 < 5 100 x x x 
84 < 10 28 x x x 
85 < 5 100 x x 49 
86 < 5 100 x x x 
87 < 5 100 x x x 
88 < 5 100 x x x 
89 < 10 42 25 x x 
90 < 5 100 x x x 
91 < 5 90 x x x 
92 < 5 42 x 416 x 
93 < 5 100 56 x 66 
94 < 5 17 x x x 
95 < 5 45 68 x x 
96 < 10 100 x x x 
97 < 5 100 81 39 57 
98 < 5 100 x 20 x 
99 < 10 100 x x 46 
100 < 5 100 x x x 
101 < 5 100 x x 16 
102 < 5 100 79 259 387 
103 < 10 100 x x x 
104 < 5 77 45 x 40 
105 < 10 77 x x 22 
106 <10 76 x x x 
107 < 5 74 x x x 
108 < 10 65 x x x 
109 < 5 62 x x x 
110 < 5 60 40 572 x 
111 < 10 58 x x x 
112 < 5 58 x 338 x 
113 < 10 58 x x x 
114 < 5 54 x x 27 
115 < 5 50 13 293 43 
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116 < 5 100 59 403 50 
117 < 5 18 x x x 
118 < 5 100 x x x 
119 < 5 33 x x x 
120 < 5 16 x x 54 
121 < 5 100 x x x 
122 < 10 26 x 388 x 
123 < 5 100 x x x 
124 < 5 39§ x x x 
125 < 5 100 x x x 
126 < 5 42 x x x 
127 < 5 92 41 x x 
128 < 6* 11
§ x 593 781 
129 < 5 3.4§ x x x 
130 < 5 86 22 153 x 
131 < 6* 100 x x x 
132 < 5 68 x x 47 
133 < 5 80 54 24 x 
134 < 5 36 x x x 
135 < 5 100 x x x 
136 < 5 100 x x x 
137 < 5 100 x x 40 
138 < 5 93 x x x 
139 < 5 100 61 x x 
140 < 5 35 x x x 
141 < 5 100 x x x 
142 < 5 100 x x x 
143 < 5 85 x x x 
144 < 5 76 x x x 
145 < 5 56 x x 171 
146 < 5 100 x x x 
147 < 5 100 x x x 
148 < 5 29 56 x x 
149 < 5 63 x x x 
150 < 5 54 114 x x 
151 < 5 31 101 x x 
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Supplemental Table 2: Detailed information on laboratory, clinical and outcome parameters of the 95 
iTTP patients of the French reference center. Identity (ID; patients 1-95 depicted here, are the same 
patients 1-95 in Table 1), sex (M: male, F: female), age (years), platelet count (x109/L), idiotope profile (1-
8), Benhamou score (< 3 (1-2) or ≥ 3 (3-4)), lactate dehydrogenase levels (LDH) level (IU/L), cerebral 
involvement and treatment. N/A: not assessed, † deceased, PEX: plasma exchange 
 
ID 
sex 
(M/F) 
age 
(years) 
platelet 
count 
(x109/L) 
idiotope 
profile 
Score by 
Benhamou 
et al.40 
LDH 
level 
(IU/L) 
cerebral 
involvement 
additional treatment 
to PEX 
1 F 66 24 5 ≥ 3 (3) < 2500 
yes (seizure, 
headaches, 
confusion) 
+ rituximab  
+ steroids 
2 F 41 8 1 < 3 (2) N/A 
yes 
(confusion) 
PEX only 
3 M 56 17 3 < 3 (2) < 2500 yes (stroke) + steroids 
4 F 65 132 7 ≥ 3 (3) < 2500 
yes 
(confusion, 
transient 
focal defect) 
+ rituximab  
+ steroids 
5 F 74 16 5 ≥ 3 (3) < 2500 yes (stroke) PEX only 
6 M 55 52 8 < 3 (1) < 2500 no 
+ rituximab  
+ steroids  
+ cyclophosphamide 
7 M 74 41 8 ≥ 3 (3) < 2500 
yes 
(confusion) 
+ rituximab  
+ steroids 
8 M 33 6 8 < 3 (1) < 2500 
yes 
(headaches, 
convulsion 
and seizure) 
+ rituximab  
+ steroids 
9 F 45 4 8 < 3 (2) ≥ 2500 no steroids only 
10 F 27 16 7 < 3 (1) < 2500 yes + steroids 
11 M 55 24 8 < 3 (1) N/A no no treatment† 
12 F 27 7 5 < 3 (0) < 2500 no + steroids 
13 M 68 23 3 ≥ 3 (3) < 2500 yes 
+ rituximab  
+ steroids 
14 F 25 13 8 < 3 (1) < 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
15 F 48 9 8 < 3 (2) < 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
16 F 31 18 1 < 3 (1) < 2500 
yes 
(confusion) 
PEX only 
17 F 37 32 8 < 3 (1) < 2500 
yes 
(headaches) 
PEX only 
13 
 
18 M 30 21 8 < 3 (0) < 2500 no 
+ rituximab  
+ steroids  
+ cyclophosphamide 
+ bortezomib 
19 F 65 14 8 ≥ 3 (3) < 2500 
yes 
(transient 
focal defect) 
+ steroids 
20 F 60 18 8 < 3 (2) ≥ 2500 no + rituximab 
21 M 48 26 8 < 3 (2) < 2500 
yes 
(confusion) 
+ rituximab 
22 F 56 27 5 < 3 (2) < 2500 
yes (stroke, 
blindness) 
+ steroids 
23 F 32 13 3 < 3 (1) < 2500 yes (aphasia) 
+ rituximab  
+ steroids 
24 F 23 12 2 < 3 (0) < 2500 no 
+ rituximab  
+ steroids 
25 M 38 16 7 < 3 (1) < 2500 
yes 
(headaches) 
+ caplacizumab 
26 F 26 7 8 < 3 (1) < 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
27 M 34 44 7 < 3 (1) < 2500 yes PEX only 
28 F 62 9 7 ≥ 3 (3) ≥ 2500 yes (aphasia) PEX only 
29 M 24 18 7 < 3 (0) < 2500 no PEX only 
30 F 38 17 3 < 3 (0) < 2500 no PEX only 
31 F 80 14 4 ≥ 3 (3) < 2500 
yes 
(confusion, 
convulsion) 
+ rituximab 
32 M 44 20 7 < 3 (2) < 2500 
yes 
(confusion, 
headaches) 
PEX only 
33 F 31 5 4 < 3 (0) < 2500 no + steroids 
34 F 71 20 1 ≥ 3 (3) < 2500 
yes 
(convulsion) 
PEX only 
35 F 31 9 2 < 3 (1) < 2500 
yes 
(headaches) 
+ rituximab 
36 F 27 20 8 < 3 (1) N/A 
yes 
(headaches) 
+ steroids 
37 F 28 5 4 < 3 (1) ≥ 2500 no + steroids 
38 F 68 5 4 ≥ 3 (3) < 2500 yes (seizure) 
+ rituximab  
+ steroids 
39 F 45 39 3 < 3 (2) < 2500 
yes 
(transient 
focal defect) 
+ rituximab  
+ steroids 
40 F 21 14 5 < 3 (2) ≥ 2500 
yes 
(confusion, 
headaches) 
+ steroids 
41 F 63 12 8 < 3 (2) < 2500 no steroids only 
42 M 35 7 5 < 3 (0) < 2500 no + rituximab 
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43 F 41 12 6 < 3 (2) N/A 
yes 
(headaches) 
+ steroids 
44 F 53 31 3 < 3 (1) N/A no + rituximab 
45 F 35 12 6 < 3 (2) ≥ 2500 
yes 
(headaches, 
visual 
disorders) 
+ steroids 
46 F 54 10 8 < 3 (2) < 2500 
yes 
(transient 
focal defect) 
+ steroids 
47 M 58 13 3 < 3 (2) < 2500 
yes 
(confusion) 
+ rituximab 
48 F 24   7 < 3 (1) < 2500 yes (aphasia) 
+ rituximab  
+ steroids 
49 F 40 10 8 < 3 (1) < 2500 
yes 
(confusion) 
+ rituximab  
+ steroids 
50 F 65 12 1 < 3 (2) < 2500 no 
+ rituximab  
+ steroids 
51 F 23 6 1 < 3 (1) < 2500 
yes 
(headaches) 
+ steroids 
52 M 20 9 8 < 3 (1) < 2500 
yes 
(headaches, 
convulsion) 
+ rituximab  
+ steroids 
53 M 52 4 8 < 3 (1) < 2500 no 
+ rituximab  
+ steroids  
+ vincristin  
+ splenectomy (anti-
vWF Abs) 
54 F 76 41 8 ≥ 3 (3) < 2500 yes (stroke) + rituximab 
55 F 53 12 3 ≥ 3 (3) ≥ 2500 
yes 
(confusion, 
convulsion) 
+ rituximab  
+ steroids 
56 F 70 30 8 ≥ 3 (3) < 2500 yes (stroke) PEX only 
57 M 41 18 7 < 3 (1) < 2500 no PEX only 
58 F 66 26 5 ≥ 3 (4) ≥ 2500 
yes 
(confusion, 
stroke) 
+ rituximab  
+ steroids 
59 F 25 12 5 < 3 (1) ≥ 2500 no + steroids 
60 M 32 10 3 < 3 (1) < 2500 yes 
+ rituximab  
+ steroids 
61 F 53 5 7 < 3 (2) < 2500 
yes (disorder 
of language) 
+ steroids 
62 F 41 13 7 < 3 (1) < 2500 no PEX only 
63 M 36 9 5 < 3 (0) N/A no PEX only 
64 F 34 8 7 < 3 (1) < 2500 yes 
+ rituximab  
+ steroids 
65 F 50 18 5 < 3 (2) < 2500 yes 
+ rituximab  
+ steroids 
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66 F 45 11 8 < 3 (2) < 2500 
yes 
(headaches, 
visual 
disorders) 
PEX only 
67 M 60 6 8 ≥ 3 (3) ≥ 2500 
yes 
(headaches) 
+ steroids 
68 F 79 82 3 ≥ 3 (3) < 2500 
yes 
(confusion, 
coma) 
+ rituximab 
69 M 65 35 6 ≥ 3 (3) < 2500 
yes (aphasia, 
confusion) 
+ steroids 
70 M 27 29 3 < 3 (1) < 2500 
yes 
(headaches) 
+ steroids 
71 F 45 6 5 < 3 (1) < 2500 no + steroids 
72 F 67 8 5 ≥ 3 (3) ≥ 2500 no 
+ rituximab  
+ steroids 
73 M 44 32 3 < 3 (1) N/A no PEX only 
74 F 37 13 6 < 3 (0) < 2500 no + steroids 
75 M 61 13 3 < 3 (2) < 2500 no PEX only 
76 M 42 10 7 ≥ 3 (3) < 2500 yes (stroke) 
+ rituximab  
+ steroids 
77 F 83 12 3 ≥ 3 (3) < 2500 yes (stroke) PEX only 
78 M 63 30 7 < 3 (2) N/A no PEX only 
79 F 64 4 5 ≥ 3 (3) < 2500 
yes 
(headaches, 
transient 
focal defect) 
+ rituximab  
+ steroids 
80 F 85 9 8 ≥ 3 (3) < 2500 
yes 
(transient 
focal defect) 
+ steroids 
81 M 83 9 3 ≥ 3 (3) < 2500 
yes 
(confusion) 
+ rituximab  
+ steroids 
82 M 61 11 6 < 3 (2) N/A no 
+ rituximab  
+ steroids  
+ cyclophosphamide  
+ splenectomy 
83 F 33 63 8 < 3 (1) < 2500 
yes 
(transient 
focal defect) 
steroids only 
84 M 40 34 8 < 3 (1) < 2500 
yes (cerebral 
lesions) 
+ steroids 
85 F 63 7 3 ≥ 3 (3) < 2500 yes (stroke) no treatment† 
86 F 40 8 8 < 3 (1) < 2500 
yes 
(headaches) 
+ steroids 
87 F 27 11 8 < 3 (0) < 2500 no + steroids 
88 F 21 11 8 < 3 (1) < 2500 
yes 
(headaches, 
transient 
focal defect) 
+ rituximab 
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89 F 31 55 1 < 3 (1) < 2500 
yes 
(headaches, 
seizure) 
+ rituximab  
+ steroids 
90 F 33 6 8 < 3 (1) < 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
91 F 46 5 8 ≥ 3 (3) ≥ 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
92 M 47 10 2 < 3 (2) N/A 
yes (seizure, 
aphasia, 
coma) 
no treatment† 
93 M 24 7 5 < 3 (1) < 2500 
yes 
(headaches) 
+ rituximab  
+ steroids 
94 M 44 7 8 < 3 (1) < 2500 no 
+ rituximab  
+ steroids 
95 F 27 8 1 < 3 (0) < 2500 no 
+ rituximab  
+ steroids 
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